Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509083 | 1.00 | RAB9A (0.54) | RAB9AALDH1A1ALOX15TSHRMAOB | |
| SCHEMBL28121251 | 0.88 | RAB9A (0.47) | RAB9AALDH1A1ALOX15TSHRMAOB | |
| SCHEMBL5572239 | 0.84 | MAOB (0.50) | RAB9AALDH1A1MAOBLMNAMAPT | |
| SCHEMBL28546334 | 0.84 | MAOB (0.50) | RAB9AALDH1A1MAOBLMNAMAPT | |
| SCHEMBL11080877 | 0.82 | RAB9A (0.55) | RAB9AALDH1A1TSHRLMNAMAPT | |
| SCHEMBL10410292 | 0.82 | L3MBTL1 (0.55) | RAB9AALDH1A1TSHRLMNAMAPT | |
| SCHEMBL10410291 | 0.82 | L3MBTL1 (0.55) | RAB9AALDH1A1TSHRLMNAMAPT | |
| SCHEMBL11080880 | 0.82 | RAB9A (0.55) | RAB9AALDH1A1TSHRLMNAMAPT | |
| SCHEMBL6516804 | 0.80 | KMT2A (0.48) | RAB9AALDH1A1MAOBLMNAHSP90AA1 | |
| SCHEMBL6516806 | 0.80 | KMT2A (0.48) | RAB9AALDH1A1MAOBLMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504724-A1 | SPLEEN TYROSINE KINASE INHIBITORS | Uniquest Pty Limited (AU) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023193054-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2023-10-12 | — | — | WO | disclosed |
| WO-2016073947-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| WO-2015009812-A2 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20080045492-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
| US-20080045492-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
| WO-2005077885-A1 | RUTHENIUM-CATALYZED HYDROAMINATION OF OLEFINS | YALE UNIVERSITY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-6603046-B1 | The invention is drawn to novel bis-aromatic a, beta -unsaturated ketones. The compounds are useful in the treatment and prophylaxis of diseases caused by parasites or bacteria. | LICA PHARMACEUTICALS A/S (DK) | 2003-08-05 | — | — | US | disclosed |
| EP-0634927-B1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | LICA PHARMACEUTICALS AS (DK) | 2001-07-04 | — | — | EP | disclosed |
| US-5985935-A | PARASITICIDES OR BACTERICIDES | STATENS SERUMINSTITUT (DK) | 1999-11-16 | — | — | US | disclosed |
| EP-0558656-B1 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES | MASSACHUSETTS INST TECHNOLOGY (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006628-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-03-09 | — | — | WO | disclosed |
| EP-0634927-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993017671-A1 | TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES, OR BACTERIA | STATENS SERUMINSTITUT (DK) | 1993-09-16 | — | — | WO | disclosed |
| EP-0558656-A1 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES. | MASSACHUSETTS INST TECHNOLOGY (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1992009545-A2 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-06-11 | — | — | WO | disclosed |
| US-4486588-A | Cyclohexadiene carboxylate insecticide intermediates | FMC CORPORATION (US) | 1984-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045492-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF23 | RAB9A 1651/4885ALDH1A1 2547/4885ALOX15 4778/4885 |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | MAVS, EIF2AK2, IRF3 | RAB9A 1595/4885ALDH1A1 3052/4885ALOX15 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.